Rallybio Co. (NASDAQ:RLYB – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 631,000 shares, an increase of 41.3% from the March 15th total of 446,700 shares. Based on an average daily trading volume, of 123,200 shares, the short-interest ratio is currently 5.1 days. Approximately 4.8% of the company’s stock are sold short.
Several research firms have recently issued reports on RLYB. Zacks Investment Research lowered shares of Rallybio from a “hold” rating to a “sell” rating in a research note on Saturday, March 19th. JMP Securities reduced their price target on shares of Rallybio from $32.00 to $29.00 and set a “market outperform” rating for the company in a research report on Wednesday, March 16th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $24.75.
In other Rallybio news, major shareholder Opportunities I. L.P. 5Am sold 210,000 shares of the company’s stock in a transaction on Tuesday, February 8th. The shares were sold at an average price of $13.05, for a total transaction of $2,740,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
NASDAQ RLYB traded up $0.50 during trading on Friday, hitting $9.03. 81,247 shares of the company’s stock traded hands, compared to its average volume of 191,630. Rallybio has a 12-month low of $6.74 and a 12-month high of $25.78. The business has a 50 day moving average of $9.76 and a 200-day moving average of $12.13.
Rallybio (NASDAQ:RLYB – Get Rating) last released its quarterly earnings data on Tuesday, March 15th. The company reported ($0.42) EPS for the quarter. As a group, equities research analysts anticipate that Rallybio will post -2.23 EPS for the current year.
Rallybio Company Profile (Get Rating)
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Get a free copy of the StockNews.com research report on Rallybio (RLYB)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.